Predictive factors of histologic response to primary chemotherapy in patients with ewing sarcoma

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 6, 2007, Pages 364-368

  Ferrari, Stefano ^a,b   Bertoni, Franco ^a   Palmerini, Emanuela ^a   Errani, Costantino ^a   Bacchini, Patrizia ^a   Pignotti, Elettra ^a   Mercuri, Mario ^a   Longhi, Alessandra ^a   Cesari, Marilena ^a   Picci, Piero ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b Chemotherapy   (Italy)

Author keywords

Age; Chemotherapy; Ewing sarcoma; Necrosis; Sex

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; VINCRISTINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CHILD; EWING SARCOMA; FEMALE; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; SEX RATIO; STATISTICAL SIGNIFICANCE; THROMBOCYTOPATHY; THROMBOCYTOPENIA; TUMOR VOLUME;

ADOLESCENT; ADULT; AGE FACTORS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SARCOMA, EWING'S; SEX CHARACTERISTICS;

EID: 34250004610     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3180640d08     Document Type: Article

References (30)

1. Bacci G, Forni C, Longhi A, et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer. 2004;40:73-83.
2. Paulussen M, Ahrens S, Dunst J, et al. Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol. 2001;19:1818-1829.
3. Grier HE, Krailo MD, Tarbel NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694-701.
4. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol. 2000;18:3108-3114.
5. Fizazi K, Dohollou N, Blay JY, et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol. 1998;16:3736-3743.
6. Aparicio J, Munarriz B, Pastor M, et al. Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution. Oncology. 1998;55:20-26.
7. Elomaa I, Blomqvist CP, Saeter G, et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer. 2000;36:875-880.
8. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4-11.
9. Picci P, Böhling T, Bacci G, et al. Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol. 1997;15:1553-1559.
10. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing's sarcoma. J Bone Joint Surg Am. 1998;80:1020-1033.
11. Oberlin O, Le Deley MC, N'Guyen Bul B, et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Pediatric Oncology (EW88 study). Br J Cancer. 2001;85:1646-1654.
12. Rosito P, Mancini AF, Rondelli R, et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer. 1999;86:421-428.
13. Gobel V, Jurgens H, Etspuler G, et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J Cancer Res Clin Oncol. 1987;113:187-191.
14. Picci P, Rougraff BT, Bacci G, et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol. 1993;11:1763-1769.
15. Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6:780-789.
16. Fujita K. Cytochrome P450 and anticancer drugs. Curr Drug Metab. 2006;7:23-37.
17. Bebia Z, Buch SC, Wilson JW, et al. Bioequivalence revisited: influence of age and sex on CYP enzymes. Clin Pharmacol Ther. 2004;76:618-627.
18. Chen CS, Lin JT, Goss KA, et al. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol. 2004;65:1278-1285.
19. Furlanut M, Franceschi L. Pharmacology of ifosfamide. Oncology. 2003;65(suppl 2):2-6.
20. Wurthwein G, Klingebiel T, Krumpelmann S, et al. Population pharmacokinetics of high-dose etoposide in children receiving different conditioning regimens. Anticancer Drugs. 2002;13:101-110.
21. Veal GJ, Cole M, Errington J, et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res. 2005;11:5893-5899.
22. Frost BM, Eksborg S, Bjork O, et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukemia: multi-institutional collaborative study. Med Pediatr Oncol. 2002;38:329-337.
23. Hempel G, Flege S, Wurthwein G, et al. Peak plasma concentrations of doxorubicin in children with acute lymphoblastic leukemia or non-Hodgkin lymphoma. Cancer Chemother Pharmacol. 2002;49:133-141.
24. Eksborg S, Palm C, Bjork O. A comparative pharmacokinetic study of doxorubicin and 4′-epi-doxorubicin in children with acute lymphocytic leukemia using a limited sampling procedure. Anticancer Drugs. 2000;11:129-136.
25. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51:395-402.
26. Gotay CC, Phillips PH, Cheson BD. Male-female differences in the impact of cancer therapy. Oncology. 1993;7:67-74.
27. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995;332:1738-1743.
28. Singh S, Parulekar W, Murray N, et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23:850-856.
29. Dobbs NA, Twelves CJ, Gillies H, et al. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36:473-476.
30. Kaul S, Srinivas NR, Mummaneni V, et al. Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients. Semin Oncol. 1996;23(suppl 13):23-29.